title: Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas.
abstract: BRCA2 is the major high-penetrance predisposition gene for luminal (estrogen receptor [ER] positive) breast cancers. However, many BRCA2 mutant carriers lack family history of breast/ovarian cancers and do not benefit from genetic testing. Specific genomic features associated with BRCA2 inactivation in tumors could help identify patients for whom a genetic test for BRCA2 may be proposed. A series of ER-positive invasive ductal carcinomas (IDCs) including 30 carriers of BRCA2 mutations and 215 control cases was studied by single-nucleotide polymorphism (SNP) arrays. Cases and controls were stratified by grade and HER2 status. Independently, 7 BRCA2 and 51 control cases were used for validation. Absolute copy number and Loss of heterozygosity (LOH) profiles were obtained from SNP arrays by the genome alteration print (GAP) method. BRCA2 tumors were observed to display a discriminatively greater number of chromosomal breaks calculated after filtering out and smoothing <3 Mb variations. This argues for a BRCA2-associated genomic instability responsible for long-segment aberrations. Co-occurrence of two genomic features-LOH of 13q13 and 14q32-was found to predict BRCA2 status with 90% of sensitivity and 87% of specificity in discovery series of high-grade HER2-negative IDCs and 100% of sensitivity and 88% of specificity in an independent series of 58 IDCs. Estimated positive predictive value was 17.2% (confidence interval: 6.7-33.5) in the whole series. In conclusion, the simplified BRCA2 classifier based on the co-occurrence of LOH at 13q13 and 14q32 could provide an indication to test for BRCA2 mutation in patients with ER-positive IDC.
authors.affiliation: Institut Curie, Centre de Recherche, Paris, France; INSERM U830, Paris, France; Department of Tumor Biology, Institut Curie, Paris, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Pécuchet
authors.forename: Tatiana
authors.initials: T
authors.lastname: Popova
authors.forename: Elodie
authors.initials: E
authors.lastname: Manié
authors.forename: Carlo
authors.initials: C
authors.lastname: Lucchesi
authors.forename: Aude
authors.initials: A
authors.lastname: Battistella
authors.forename: Anne
authors.initials: A
authors.lastname: Vincent-Salomon
authors.forename: Virginie
authors.initials: V
authors.lastname: Caux-Moncoutier
authors.forename: Marc
authors.initials: M
authors.lastname: Bollet
authors.forename: Brigitte
authors.initials: B
authors.lastname: Sigal-Zafrani
authors.forename: Xavier
authors.initials: X
authors.lastname: Sastre-Garau
authors.forename: Dominique
authors.initials: D
authors.lastname: Stoppa-Lyonnet
authors.forename: Marc-Henri
authors.initials: MH
authors.lastname: Stern
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D002869:Chromosome Aberrations; D002882:Chromosomes, Human, Pair 13; D002883:Chromosomes, Human, Pair 14; D005260:Female; D024522:Genes, BRCA2; D006801:Humans; D019656:Loss of Heterozygosity; D008875:Middle Aged; D009154:Mutation; D011003:Ploidies; D020641:Polymorphism, Single Nucleotide
keywords: BRCA2; SNP-array; breast cancer; oncogenetics